WallStreetZenWallStreetZen

NASDAQ: CDTX
Cidara Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CDTX past revenue growth

How has CDTX's revenue growth performed historically?
Company
-7.75%
Industry
110.58%
Market
14.02%
CDTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CDTX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance

CDTX earnings and revenue history

Current Revenue
$56.5M
Current Earnings
-$31.4M
Current Profit Margin
-55.5%

CDTX Return on Equity

Current Company
-264.8%
Current Industry
15.6%
Current Market
-8.4%
CDTX's Return on Equity (-264.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CDTX announces earnings.

CDTX Return on Assets

Current Company
-48.1%
Current Industry
2.2%
CDTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CDTX Return on Capital Employed

Current Company
-111.54%
Current Industry
17.7%
CDTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CDTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CDTX$56.54M-$30.03M-$31.37M+31.17%N/A
CSBR$52.69M-$5.34M-$7.58M+19.71%N/A
CRIS$10.21M-$45.43M-$47.03M-1.35%N/A
CLSD$2.21M-$37.25M-$37.32M+109.34%N/A
CARA$21.23M-$114.69M-$116.52M+21.74%N/A
View Top Biotech Stocks

Cidara Therapeutics Earnings & Revenue FAQ

What were CDTX's earnings last quarter?

On Invalid Date, Cidara Therapeutics (NASDAQ: CDTX) reported Q3 2023 earnings per share (EPS) of -$0.09, up 152.94% year over year. Total Cidara Therapeutics earnings for the quarter were -$8.17 million. In the same quarter last year, Cidara Therapeutics's earnings per share (EPS) was $0.17.

If you're new to stock investing, here's how to buy Cidara Therapeutics stock.

What was CDTX's earnings growth in the past year?

As of Q4 2023, Cidara Therapeutics's earnings has grown year over year. Cidara Therapeutics's earnings in the past year totalled -$31.37 million.

What was CDTX's revenue last quarter?

On Invalid Date, Cidara Therapeutics (NASDAQ: CDTX) reported Q3 2023 revenue of $12.72 million up 68.79% year over year. In the same quarter last year, Cidara Therapeutics's revenue was $40.74 million.

What was CDTX's revenue growth in the past year?

As of Q4 2023, Cidara Therapeutics's revenue has grown -7.75% year over year. This is 118.33 percentage points lower than the US Biotechnology industry revenue growth rate of 110.58%. Cidara Therapeutics's revenue in the past year totalled $56.54 million.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.